Other analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of XBiotech from a “hold” rating to a “sell” rating in a research report on Saturday, September 28th. ValuEngine downgraded shares of XBiotech from a “hold” rating to a “sell” rating in a research report on Wednesday. Finally, Piper Jaffray Companies initiated coverage on shares of XBiotech in a research report on Friday, June 14th. They issued an “overweight” rating and a $13.00 price objective for the company.
NASDAQ XBIT traded down $0.25 during mid-day trading on Friday, hitting $9.06. The company’s stock had a trading volume of 11,180 shares, compared to its average volume of 150,048. XBiotech has a 52-week low of $3.12 and a 52-week high of $11.74. The stock’s fifty day simple moving average is $9.00 and its two-hundred day simple moving average is $8.61. The firm has a market capitalization of $382.21 million, a P/E ratio of -15.41 and a beta of 0.44.
A number of large investors have recently modified their holdings of XBIT. Marshall Wace LLP acquired a new stake in XBiotech in the first quarter valued at approximately $682,000. Strs Ohio acquired a new stake in XBiotech in the second quarter valued at approximately $357,000. JPMorgan Chase & Co. acquired a new stake in shares of XBiotech during the second quarter worth approximately $34,000. Charles Schwab Investment Management Inc. acquired a new stake in shares of XBiotech during the second quarter worth approximately $309,000. Finally, Bank of New York Mellon Corp grew its position in shares of XBiotech by 217.8% during the second quarter. Bank of New York Mellon Corp now owns 53,136 shares of the biopharmaceutical company’s stock worth $403,000 after buying an additional 36,415 shares in the last quarter. 10.75% of the stock is owned by institutional investors.
XBiotech Company Profile
XBiotech Inc, a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is bermekimab, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer.
Featured Story: Quick Ratio
Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.